Alexion Announces Executive Leadership Changes
May 23 2017 - 8:00AM
Business Wire
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the
following changes to its executive leadership team:
- Brian Goff is joining Alexion as Chief
Commercial Officer, effective June 1, 2017. Mr. Goff is a veteran
biopharmaceutical executive with more than 25 years of experience
at companies including Neurovance, Inc., Baxalta, Inc., Baxter,
Novartis and Johnson & Johnson. Mr. Goff will lead all
commercial operations globally with responsibility for country
operations in each of Alexion’s affiliates in North
America, EMEA, Japan, Asia Pacific, and Latin America. He
succeeds Carsten Thiel who is leaving the Company to pursue new
opportunities effective June 1, 2017.
- Dave Anderson, Chief Financial Officer,
will resign his position at the end of August. A search for a new
CFO is underway with SpencerStuart.
- Martin Mackay, Executive Vice
President, Head of Research & Development will be retiring from
Alexion at the end of 2017. A search is also underway for a new
Head of R&D with SpencerStuart.
- Clare Carmichael, Executive Vice
President, Chief Human Resources Officer, will be leaving the
Company to pursue new opportunities effective June 1, 2017.
Recruiting is underway for a new Head of Human Resources.
Ludwig Hantson, Alexion’s Chief Executive Officer, stated, “We
are delighted to welcome Brian to Alexion as our new Chief
Commercial Officer and look forward to his leadership in developing
and executing our strategies for long-term growth as we focus on
creating value for all stakeholders. He brings to Alexion the
expertise and proven track record that will help us continue to
build on our global leadership position, as well as a passion for
developing talent and cultivating a high-performing culture. At the
same time, we thank Carsten for his many contributions to Alexion’s
success over the past three years. He has played a critical role in
bringing Alexion’s innovative therapies to patients with rare and
devastating diseases around the world and establishing a solid
foundation for the future.”
Mr. Goff said, “I am very excited to join Alexion and have long
admired the Company’s leadership in rare diseases, commitment to
breakthrough medical innovation, patient-centric focus, and
successful growth trajectory. I look forward to leading the
Commercial organization and to being part of the team that will
take Alexion to its next chapter of growth.”
With respect to Dave Anderson, Dr. Hantson commented, “I have
valued Dave’s partnership and we are grateful for his many
contributions to the Company and the finance function during an
important transition period. We also appreciate his continued
dedication to Alexion as our active CFO until the end of August, at
which time it is our expectation that we will have retained a new,
world-class CFO.”
Mr. Anderson added, “With Ludwig now firmly onboard as our CEO
and Alexion off to a strong start in 2017, this presents the
opportunity for the Company to identify a top-talent CFO who can
partner with Ludwig to drive growth and profitability over the long
term. I look forward to supporting Alexion and the team in the
coming months to execute a seamless transition.”
With respect to identifying a new Head of R&D, Dr. Hantson
said, “The R&D function at Alexion is core to our business and
to our future, and it is our intent to recruit a new Head of
R&D who can build on Martin’s successes. During his time at
Alexion, Martin distinguished himself as a leader in researching
and developing promising therapies for rare diseases while building
an outstanding R&D leadership team and organization. Martin
also led the development of Strensiq, bringing the first enzyme
replacement therapy to market for patients with hypophosphatasia,
and significantly advanced our complement pipeline programs. All of
us at Alexion appreciate his dedication to patients and his efforts
to position Alexion on the leading edge of innovation as we work to
address some of the rarest, life-threatening conditions.”
Commenting on a new Head of Human Resources, Dr. Hantson said,
“As Alexion advances our pipeline and commercial growth priorities,
we will appoint a new Head of Human Resources who will leverage
Clare’s achievements in attracting and retaining the highest levels
of talent required to serve patients across the globe. Since she
joined the Company in 2011, Alexion has grown from approximately
800 to 3,000 employees, and we are grateful for Clare’s leadership
in helping us design the structure and systems to operate globally
in 50 countries. In addition, she significantly expanded our global
talent initiatives, including talent management, training and
development, and compensation and benefits. The Alexion team wishes
Clare well and thanks her for her commitment to our mission and our
people.”
Brief Biography of Brian Goff
Mr. Goff is a proven global biopharmaceutical executive with a
25-year track record of consistently delivering sustainable growth
through multiple business cycles. He has deep expertise in
commercial operations across multiple therapeutic areas, as well as
broad experience in managing a range of functions, including
R&D, Medical Affairs, Manufacturing and Quality with a number
of industry-leading biopharmaceutical companies.
Most recently, Mr. Goff served as Chief Operating Officer and a
Member of the Board of Directors of Neurovance, Inc., from December
2016 until the company was acquired by Otsuka Pharmaceuticals Co.
in March 2017. Previously, Mr. Goff served as Baxalta’s Executive
Vice President & President – Hematology Division, from the time
of the company’s spin-off from Baxter International Inc. in 2015
until its combination with Shire in mid-2016. From June
2012-December 2014, he served with Baxter Healthcare Corporation as
Global Hemophilia Franchise Head. Earlier in his career, Mr. Goff
held positions of increasing responsibility in sales and marketing
roles with Novartis Pharmaceuticals, and the pharmaceutical
division of Johnson & Johnson.
He earned his M.B.A. from the Wharton School at the University
of Pennsylvania and his B.A. from Skidmore College.
About Alexion
Alexion is a global biopharmaceutical company focused on
developing and delivering life-transforming therapies for patients
with devastating and rare disorders. Alexion is the global leader
in complement inhibition and has developed and commercializes the
first and only approved complement inhibitor to treat patients with
paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic
uremic syndrome (aHUS), two life-threatening ultra-rare disorders.
In addition, Alexion’s metabolic franchise includes two highly
innovative enzyme replacement therapies for patients with
life-threatening and ultra-rare disorders, hypophosphatasia (HPP)
and lysosomal acid lipase deficiency (LAL-D). Alexion is advancing
its rare disease pipeline with highly innovative product candidates
in multiple therapeutic areas. This press release and further
information about Alexion can be found
at: www.alexion.com.
[ALXN-G]
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements often include words such
as "anticipate," "believe," "expect," "will," or similar
expressions. Forward-looking statements are subject to factors that
may cause Alexion's results and plans to differ from those
expected, including for example, risks related to potential
disruptions to our business as a result of leadership changes, and
a variety of other risks set forth from time to time in Alexion's
filings with the U.S. Securities and Exchange Commission, including
but not limited to the risks discussed in Alexion's Quarterly
Report on Form 10-Q for the period ended March 31, 2017 and in our
other filings with the U.S. Securities and Exchange Commission.
Alexion does not intend to update any of these forward-looking
statements to reflect events or circumstances after the date
hereof, except when a duty arises under law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170523005516/en/
Alexion:MediaKim
Diamond, 475-230-3775Executive Director, Corporate
CommunicationsorInvestorsElena Ridloff, CFA,
475-230-3601Vice President, Investor RelationsorCatherine Hu,
475-230-3599Director, Investor Relations
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Sep 2023 to Sep 2024